Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

NCT07131345 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Malignant Mesothelioma
Mesothelioma

Interventions

DRUG: iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy

Sponsor

National Cancer Center, China

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]